trending Market Intelligence /marketintelligence/en/news-insights/trending/s41oesvqu7y0yoxaydt4gg2 content esgSubNav
In This List

PDL BioPharma no longer pursuing Neos Therapeutics

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


PDL BioPharma no longer pursuing Neos Therapeutics

PDL BioPharma Inc. said it is no longer looking to acquire Neos Therapeutics Inc.

The Incline Village, Nev.-based biotech company had offered to buy Texas-based Neos for $10.25 per share in cash, but its offer had been rejected by the target company's board.

"While we believe we have provided a compelling opportunity for Neos' shareholders, we were unable to agree on terms that were in the best interest of our shareholders. We continue to pursue other opportunities and be disciplined in the process," PDL CEO John McLaughlin said in a statement.